A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/69448/MonH-2020-243697(v2)
NMA SSA Reference Number: SSA/69448/MonH-2021-254708(v2)
Monash Health Reference: RES-20-0000-808A
Effective start/end date4/03/213/03/26


  • clinical trial
  • phase 3 study
  • treatment safety
  • treatment efficacy
  • Myelofibrosis